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Abstract
Background: Ras associated with diabetes (Rad) inhibits vascular lesion formation by reducing the attachment and
migration of vascular smooth muscle cells (VSMCs). However, the transcriptional regulation of Rad in VSMCs is unclear.
Methodology and Principal Findings: We found that Platelet-Derived Growth Factor (PDGF)induced Rad expression in a
time- and dose-dependent manner in rat aortic smooth muscle cells (RASMCs) using quantitative real-time PCR. By serial
deletion analysis of the Rad promoter, we identified that two GC-rich early growth response-1 (Egr-1) binding sites are
essential for PDGF-induced Rad promoter activation. Overexpression of Egr-1 in RASMCs strongly stimulated Rad expression
while the Egr-1 corepressor, NGFI-A binding protein 2 (NAB2), repressed PDGF-induced Rad up-regulation in a dose-
dependent manner. Direct binding of Egr-1 to the Rad promoter region was further confirmed by chromatin
immunoprecipitation assays.
Conclusions: Our results demonstrate that Rad is regulated by PDGF through the transcriptional factor Egr-1 in RASMCs.
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Introduction
Ras associated with diabetes (Rad) is a member of the RGK
family which is composed of Rad, Gem/Kir, Rem and Rem2 [1].
It is expressed in the heart, skeletal muscle and lung [2]. Rad is
highly expressed in the skeletal muscle of some type II diabetic
patients [2], which suggests that Rad is related with glucose
metabolism and insulin resistance. Our previous studies demon-
strate that Rad is critical in maintaining normal cardiac functions.
Rad expression decreases significantly in human failing hearts and
Rad knockout (KO) mice are more susceptible to cardiac
hypertrophy with increased CaMKII phosphorylation compared
with their littermate controls [3]. Our findings as well as the
others’ indicate that Rad inhibits myocardium L-type calcium
channel activity and attenuates the b-Adrenergic Receptor (b-AR)
activity [4,5]. Dominant negative suppression of endogenous Rad
in the heart up-regulate L-type Ca
2+ channel expression on the
plasma membrane, leading to ICa,L increase and action potential
prolongation [6]. Rad is upregulated in vascular smooth muscle
cells (VSMCs) during the formation of vascular lesions and
overexpression of Rad attenuated neointimal formation by
strongly inhibiting smooth muscle migration [7]. However, the
molecular mechanism for the induction of Rad during vascular
lesion formation is unknown.
Platelet-derived growth factor (PDGF) plays an important role
in normal tissue growth and the patho-physiological processes of
vascular diseases like atherosclerosis and restenosis [8]. During the
initiation and progression of atherosclerosis, VSMCs are activated
by growth factors like PDGF or cytokines, then proliferate and
migrate from the media into the intimal surface of the vessel, thus
facilitating neointimal formation [8]. Egr-1 is a zinc-finger
transcription factor that regulates cell proliferation and differen-
tiation [9]. It is an immediate-early response protein that is rapidly
and transiently stimulated by various growth factors including
PDGF [10]. Egr-1 regulates gene transcription by the specific
binding of its DNA binding domain, which consists of three zinc
fingers, to the consensus GC-rich regions in the promoter of its
target genes [11]. Structure analysis of Egr-1 identified a 34 amino
acids inhibitory domain (R1) at the 59 zinc finger binding region
[12]. Two corepressors, NGFI-A-binding proteins 1 and 2 (NAB1
and NAB2) can markedly decrease Egr-1 transcriptional activity
by binding to this domain [13,14].
In the present study, we set out to explore how Rad is
transcriptionally regulated in VSMCs. We found PDGF induced
Rad expression in a dose- and time-dependent manner, which
Egr-1 and its partners mediated this induction.
Results
PDGF induces Rad expression in RASMCs
To determine the effects of the growth factor PDGF on Rad
expression in RASMCs, we treated cultured RASMCs with PDGF
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e19408(20 ng/ml) for 0, 0.5, 1, 2 and 6 hours. Quantitative real-time
PCR revealed that expression of Rad increased 0.5 hours after
PDGF stimulation, peaked at 1 hour, and returned to the baseline
levels 6 hours later (Figure 1A). Rad was induced by PDGF in a
dose-dependent manner (Figure 1B). One hour of 20 ng/ml
PDGF treatment resulted in a 3.5-fold increase in Rad mRNA,
compared to untreated cells (Figure 1B).
To identify the mechanisms by which PDGF activates Rad
expression, we isolated Rad promoter and made reporter
constructs containing different length Rad promoters. RASMCs
were transfected with these constructs and then treated with
PDGF. PDGF stimulated Rad promoter activity in all Rad
promoter constructs except pRad-57, which also lacked basal
promoter activity (Figure 1C).
Egr-1 binding sites in the Rad promoter are required for
PDGF-induced Rad promoter activation
Computer analysis revealed two GC-rich regions that may serve
as Egr-1 binding sites within the 2155 to 257 bp region of the
Rad promoter (Figure 2A). To investigate whether these are
functional Egr-1 binding sites, we over-expressed a constitutively
active Egr-1 (Egr-1*) and tested whether it could transactivate Rad
promoter. Egr-1* over-expression resulted in a ,25-fold increases
of the pRad-155bp promoter activity compared with pcDNA3.1
vector transfection(Figure 2B). Then we mutated one or both of
the predicted Egr-1 binding sites in the pRad-155 construct and
co-transfected wild-type or mutant reporter constructs with a
constitutive active Egr-1* expression construct into 293A cells.
Disruption of the first Egr-1 binding site in position -74 (pRad-
155m1) caused a slight decrease in the Rad promoter activity but
the induction upon Egr-1* overexpression remain unchanged
(Figure 2B). However, disruption of the second Egr-1 binding site
in position -62 (pRad-155m2) resulted in a weaker induction of the
Rad promoter activity by Egr-1* (,7 folds) compared with the 25-
fold activation in the pRad-155 construct, whereas the basal level
remained unchanged. However, mutations on both Egr-1 binding
sites (pRad-155m3) impaired both basal and Egr-1*-induced
transactivation of the Rad promoter (Figure 2B).
To further test whether Egr-1 binding site mutation affects
PDGF-induced Rad promoter activation, we transfected RASMCs
with wild-type (pRad-155) or Egr-1 binding site mutant constructs
and then treated the cells with PDGF. PDGF triggered a nearly 3
fold promoter activity induction on pRad-155, and the induction
dropped to ,1.8 fold in pRad-155m1, and no PDGF induction
could be observed in pRad-155m2 construct meanwhile the basal
activity of these constructs remained consistent. When both Egr-1
binding sites were disrupted as in pRad-155m3, the basal level of
the Rad promoter activity dropped dramatically and no induction
by PDGF was found (Figure 2C). These results are consistent with
the above experiments performed in 293A cells overexpressing a
constitutive active Egr-1*. Furthermore, mutation of both Egr-1
binding sites in the pRad-3050 reporter construct caused , 54%
decrease in the basal level of pRad-3050 promoter activity and
PDGF-induced promoter activation was also completely abolished
in pRad-3050m (Figure 2D). Taken together, the Egr-1-responsive
regions located at 262 and 274 bp of Rad promoter are essential
for PDGF-induced Rad promoter activation.
Egr-1 mediates PDGF-induced Rad expression in RASMCs
Egr-1 was activated by various growth factors including PDGF,
and we also found a remarkable induction of Egr-1 by PDGF in
RASMCs (data not shown). Real-time quantitative PCR and
Western blot demonstrated that Egr-1 markedly induced Rad
expression at both mRNA and protein levels (Figure 3), which is
consistent with Egr-1 transactivation of the Rad promoter. These
results suggest that Egr-1 is a potent transcriptional activator for
Rad. We hypothesized that PDGF induced Rad expression via the
activation of Egr-1. NAB2 functions as a corepressor of Egr-1[14],
Figure 1. PDGF induces Rad expression in RASMCs. (A) Time
course of Rad expression level in RASMCs after 20 ng/ml PDGF-BB
treatment. (B) Dose-response of Rad expression after 1 hour treatment
with the indicated concentrations of PDGF-BB. Rad expression was
detected by real-time PCR and normalized by 18S (n=3, * p,0.05,
** p,0.01). (C) Responses of different Rad promoter reporters to PDGF-
BB stimulation in RASMCs (n=4, ** p,0.01).
doi:10.1371/journal.pone.0019408.g001
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PDGF-induced Rad expression. RASMCs were infected with a
recombinant adenovirus expressing NAB2 (Ad-NAB2) followed by
PDGF treatment for 1 hour. Ad-GFP was used as a control in this
experiment. We found that Rad expression increased in response
to PDGF in Ad-GFP-infected RASMCs, and overexpression of
NAB2 resulted in a dose-dependent abrogation of PDGF-induced
Rad expression (Figure 4A). The induction of Rad mRNA was
completely abolished when Ad-NAB2 reached a concentration of
250 MOI (multiplicity of infection). Furthermore, NAB2 inhibited
Rad promoter activity elevated by PDGF-BB (Figure 4B). These
results support that Egr-1 is a key mediator involved in PDGF-
induced Rad expression in RASMCs.
PDGF enhances Egr-1 binding to Rad promoter
ChIP assay was performed to further confirm the physiolog-
ical relevance and functionality of Egr-1 through its putative
binding sites in the Rad promoter. RASMCs untreated or
treated with PDGF for 1 hour were incubated with formalde-
hyde to cross-link protein and binding sites in DNA. The -213 to
-2 region of the Rad promoter region was amplified by PCR.
After PDGF treatment, Egr-1 was found to bind to the Rad
promoter. As for DNA from untreated cells or DNA precipitated
by control IgG, we did not find any PCR amplifications
(Figure 5). Our data strongly support that Egr-1 bound to the
proximal Rad promoter following PDGF treatment in
RASMCs.
Figure 2. Egr-1 binding sites are essential for Rad promoter activation. (A) Nucleotide sequence between base pairs -76 and -51bp of Rad
promoter. Egr-1 binding sites are boxed. The mutated bases are indicated in boldface. (B) Wild-type and mutant forms of pRad-155 were
cotransfected with pcDNA3.1-Egr-1* or pcDNA3.1 into 293A cells and luciferase activity were determined. The fold induction of Lucifearse activity by
Egr-1 was shown in the lower panel; (C) RASMCs were transfected with pRad-155 promoter reporter or its mutant forms then treated with PDGF and
luciferase activity were determined (n=4, **p,0.01). (D) pRad-3050 and pRad-3050m were transfected into RASMCs then treated with PDGF and
luciferase activity were determined (n=4, **p,0.01).
doi:10.1371/journal.pone.0019408.g002
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In the present study, we provide the first evidence that PDGF
induces Rad expression in a time- and dose-dependent manner in
rat aortic smooth muscle cells, and that Egr-1 is a key
transcriptional factor to mediate PDGF-induced Rad expression.
Rad is a RGK-family small GTPase initially identified by
subtractive cloning and found to be over-expressed in skeletal
muscle of a group of patients with type II diabetes [2]. Rad
possesses a structurally unique Ras-related core and COOH-and
NH2-terminal extensions but lacks the CAAX-like prenylation
motif at the COOH terminus possessed by Ras [15,16]. In
atherosclerotic lesions, PDGF released from inflammatory and
immune cells promotes VSMCs proliferation and attracts VSMCs
to migrate from media to intima [17]. In different animal models
of acute arterial injury, VSMCs accumulation in lesions is
inhibited by the administration of various PDGF pathway
inhibitors, including neutralizing PDGF antibodies [18], PDGFR
kinase inhibitors [19], and PDGFR-neutralizing antibodies [20].
Here we demonstrated that PDGF stimulated Rad expression in
RASMCs in a time- and dose-dependent manner. Our previous
study indicated that Rad is a critical mediator that reduces
vascular lesion formation by suppressing the attachment and
migration of VSMCs via inhibition of Rho/ROK activity [7]. Rad
induced by PDGF may serve as a suppressor for PDGF induced
smooth muscle cell migration.
We have identified that normal Rad level is critical in
maintaining cardiac and blood vessel functions. Rad expression
decreases in human failing hearts and Rad knockout (KO) mice
Figure 3. Egr-1 induces Rad expression. (A) RASMCs were infected
with Ad-Egr-1or Ad-GFP for 24 hours. Rad mRNA levels were detected
by real-time PCR (n=3, **p,0.01 vs. control); (B) Rad protein levels
were determined by Western blotting analysis. Expression of b-actin
was detected as the control for equal loading.
doi:10.1371/journal.pone.0019408.g003
Figure 4. Egr-1 is an essential mediator for PDGF induced Rad
expression. (A) RASMCs were infected with Ad-NAB2 at MOI of 0,
50,100,150 and 250 before treated with PDGF-BB (20 ng/ml) for 1 hour.
Ad-GFP was added to keep the amount of adenovirus consistent. Rad
mRNA was quantified using real-time PCR (n=3, *p,0.05, **p,0.01); (B)
RASMCs were transfected with pRad-155 and infected with Ad-NAB2 or
Ad-GFP for 24 hours and then stimulated with PDGF. Luciferase activity
was measured 1 hour after PDGF stimulation (n=4, *p,0.05,
**p,0.01).
doi:10.1371/journal.pone.0019408.g004
Figure 5. Egr-1 binds to Rad promoter after PDGF treatment.
ChIP assay was performed in RASMC stimulated with or without PDGF
(20 ng/ml) for 1 hour. After formaldehyde cross-linking, the protein-
DNA complexes were recovered using anti-Egr-1 antibody or non-
specific IgG. PCR was performed to detect the proximal Rad promoter.
PCR products were detected by 2% agarose gel electrophoresis.
doi:10.1371/journal.pone.0019408.g005
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myocardium L-type calcium channel activity and attenuates the b-
Adrenergic Receptor (b-AR) activity [4,5]. In blood vessel, Rad
expression increases significantly after balloon injury. Unlike other
small GTPase, the RGK family proteins are regulated at the
transcriptional level. However, the understanding for Rad
transcriptional regulation is very limited. Potential E box
sequences (CANNTG), which could serve as binding sites for the
HLH family transcription factors like myf5, MyoD, myogenin and
MRF4, are predicted in the Rad proximal promoter region [21].
Rad expression increases significantly during skeletal muscle
regeneration. Myogenic transcriptional factors like MEF2, MyoD
and Myf-5 can increase the transcriptional activity of Rad
promoter[22].
Until now, the molecular mechanism by which Rad is activated
during vascular lesions formation is not clear. Rad promoter
activity increased after PDGF treatment, suggesting that PDGF
induces Rad expression at transcriptional level. Deletion and
mutation analysis of Rad promoter revealed that potential Egr-1
binding sites would be critical for PDGF-induced Rad expression.
It has been well documented by us and other groups that PDGF
induces dramatic expression of Egr-1 [23]. Our data showed that
Egr-1 activated the Rad promoter in RASMCs, and overexpres-
sion of Egr-1 resulted in a marked increase at Rad mRNA and
protein levels in RASMCs. Egr-1 activity is negatively regulated by
NGFI-A-binding proteins 1 and 2 (NAB 1 and NAB 2). Binding of
NAB2 to Egr-1 through interaction between the NCD1 (NAB
conserved domain 1, NCD1) and the R1 domain of Egr-1
represses the transcriptional activity mediated by Egr-1[14]. We
found that up-regulation of Rad induced by PDGF-BB was
inhibited by the co-repressor NAB2 in a dose-dependent manner.
Together, these data support that Egr-1 and its interacting
partner(s) are the key mediators responsible for PDGF-induced
Rad expression.
Egr-1 expression is strikingly elevated in the VSMCs of
atherosclerotic lesions [24] and plays critical roles in regulating
VSMCs growth and intimal thickening after vascular injury [25].
Egr-1 binds preferentially to GC-rich regions of the promoters of
its target genes [26]. ChIP assay indicated that after PDGF
stimulation, Egr-1 binded to the proximal Rad promoter region.
Serial deletions of the Rad promoter also defined a 2155 to
257 bp region responsible for both basal and Egr-1-inducible
promoter activity. Two GC-rich motifs were predicted in this
region as potential binding sites for Egr-1. Mutation of both Egr-1
binding sites in pRad-3050 and pRad-155 resulted in dramatic
reduction in Rad basal promoter activity and complete abolish-
ment of PDGF-induced Rad promoter activation. Egr1-activated
Rad promoter activity was attenuated when the putative Egr-1
binding site at position -62 or both binding sites were mutated.
Consistent with this, PDGF-stimulated Rad promoter activation
was abolished when the putative Egr-1 binding site in position -62
or both binding sites were mutated. These results suggest that the
Egr-1 response element located at 262 bp plays the crucial role in
PDGF-induced Rad promoter activity.
Here we identified Rad as another target gene of transcriptional
factor Egr-1. After vascular cell injury, Egr-1 is expressed
primarily in the nucleus and is capable of altering the transcription
of several genes implicated in the pathogenesis of vascular disease,
including PDGF, FGF-2, TNFa, tissue factor, ICAM and p53.
Genes activated by Egr-1 play important roles in VSMC
proliferation, neointima formation and contribute to the develop-
ment of vascular diseases. Many of those genes like PDGF are
activated by Egr-1 and further induce Egr-1 expression.
Osteopontin and Egr-1 also positively regulate each other in
VSMCs, which may play an important role in controlling
inappropriate remodeling of vessel walls [27]. These positive
feedback loops amplify gene transcription activated by Egr-1. On
the other hand, the negative feedback loop between Egr-1 and
other genes like NAB2 prevents the permanent activation of Egr-1
target genes. In response to extracellular stimuli Egr-1 induces the
expression of NAB2, which in turn represses the activity of Egr-1
through binding to the R1 domain of Egr-1 [28]. Gene expression
profiling by microarrray analyses revealed enhanced expression of
several Egr family members in the hearts of Rad Knockout mice
compared with their wild-type littermates. These raised the
possibility that there is a negative feedback loop between Rad
and Egr-1, i.e. Egr-1 activation induced Rad expression and Rad
inhibited the further activation of Egr-1. Furthermore, the effect of
Rad on other transcription factors involved in neointima
formation and VSMC migration remains to be further investigat-
ed.
Materials and Methods
Cell Cuture
Rat aortic smooth muscle cells (RASMCs) were isolated from
male Sprague-Dawley rats as described previously [23] and
cultured in Dulbecco’s modified Eagle’s medium supplemented
with 10% FBS in a 5% CO2 humidified atmosphere at 37uC.
Early passages (5 to 9) of cells grown to 80-90% confluence were
used for all experiments. Cells were placed in serum-free medium
for 24 hours before treatment with PDGF-BB (Sigma).This study
was carried out in strict accordance with the recommendations in
the Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health. Experiments were approved by the
Peking University Animal Care and Use Committee (Permit
Number: IMM-XiongJW-2).
Plasmids and adenoviral recombinants
The pcDNA3.1-Egr-1* plasmid containing constitutively active
Egr-1 as well as the adenoviruses Ad-Egr-1 and Ad-NAB2 were
prepared as described previously [29]. Fragments of the Rad
promoter region (3050 bp, 1040 bp, 155 bp and 57 bp) were
amplified by PCR and subcloned into the pGL3-basic vector to
generate the pRad-3050, pRad-1040, pRad-155 and pRad-57
reporter constructs. These constructs were confirmed by DNA
sequencing.
RNA Isolation and Quantitative Real-time PCR
Total RNA was extracted from cultured RASMCs with Trizol
(Invitrogen) and 1 mg was used for cDNA synthesis using a first
strand cDNA synthesis kit according to the manufacturer’s
instructions (Invitrogen). Rad mRNA level was assessed by real-
time quantitative RT-PCR as previously described [7] and 18S
level was measured for normalization of variations in RNA input
and cDNA synthesis.
Western Blot Analyses
Cells were lysed with lysis buffer (Cell Signaling Technology).
The lysates were resolved on 12% SDS-polyacrylamide gels, and
proteins were then transferredto PVDF membranes (Bio-Rad). The
membranes were blocked for 1 hour at room temperature and
incubatedovernight at 4uC withanti-Radantibody (1:2000).Rabbit
anti-Rad polyclonal antibodywasa kind gift from Dr.RonaldKahn
[30]. Blots were then incubated with anti-rabbit secondary antibody
(1:2000) for 1 hour at room temperature and the Rad/antibody
complexes were visualized by chemiluminescence (Bio-Rad)
according to the manufacturer’s recommendations.
PDGF Induces Rad Expression through Egr-1
PLoS ONE | www.plosone.org 5 April 2011 | Volume 6 | Issue 4 | e19408Transient Transfection and Luciferease Assays
Transfection of RASMCs or 293A cells were performed using
LipofectamineTM2000 (Invitrogen) according to the manufactur-
er’s instructions. The pRL-CMV plasmid was cotransfected as the
control for transfection efficiency. Luciferase activity was mea-
sured by the Dual Luciferase Reporter System using a TD20/20
Luminometer (Turner Biosystems).
Site-Directed Mutagenesis
Mutations were introduced in the pRad-155 or pRad-3050
plasmids using QuikChange II XL Site-Directed Mutagenesis Kit
(Stratagene) according to the manufacturer’s recommendations.
The following oligonucleotides were used to create the desired
mutations: Egr1-mut1 (for pRad-155), 59-CCGCAGCGTG-
GACCGTTTTCGGGAGCGGGGGCGG-39; Egr1-mut2 (for
pRad-155), 59-GACCGGGGGCGGGAGCGTTTTCGGGTG-
GAGGCTTAAAT-39; and Egr1-mut3 (for pRad-155 and pRad-
3050), 59-GGACCGTTTTCGGGAGCGTTTTCGGGTGGA-
GGCTTAAATA-39. The mutated nucleotides are indicated in
bold. Mutations were confirmed by DNA sequencing. The
resulting pRad-155 mutants with one or both Egr1 binding sites
mutated were designated pRad-155m1, pRad-155m2 and pRad-
155m3. pRad-3050 with both Egr1 binding sites mutated was
designated pRad-3050m.
Chromatin Immunoprecipitation (ChIP)
ChIP assay was performed using a chromatin immunoprecip-
itation assay kit (Upstates). Cultured RASMCs were treated with
PDGF or vehicle for 1 hour. Proteins were cross-linked with DNA
by 1% formaldehyde treatment for 10 minutes at 37uC. Cells were
then lysed and DNA was sheared by sonication (MicrosonTM,
strength 40%, pulse 10 seconds, 4 times). The sonicated DNA was
diluted in ChIP dilution buffer. The diluted cell supernatant was
pre-cleared with protein A agarose before immunoprecipitation
with anti-Egr-1 antibody (Santa Cruz) or non-specific IgG. The
immune complexes were collected by adsorption to protein A
agarose, precipitated by gentle centrifugation at 3,000 rpm of 4uC
for 1 min, and the supernatant containing unbound nonspecific
DNA was discarded. The precipitate was washed and the immune
complexes were eluted, adjusted to 200 mM NaCl and incubated
at 65uC for 5 hours to reverse the crosslinks. After successive
treatments with RNase A and proteinase K, the DNA was
extracted with phenol-chloroform, precipitated with ethanol and
resuspended in H2O. The immunoprecipitated DNA were
analyzed by PCR with primers spanning -213 to -2 of the Rad
promoter. The primer sequences were as follows: forward: 59-
TCGCTCTCTCTCTCCTTCTCACAC-39 and reverse: 59-AC-
CCTCTTCCTCGGACCTTACATC-39. An aliquot of the
sonicated DNA was used as the input. PCR products were
detected by 2% agarose gel electrophoresis.
Statistical Analysis
Each experiment was repeated for a minimum of three times.
Statistics were analyzed using either ANOVA (for multiple
comparisons) or Student’s 2-tailed t test for comparing two means.
Data are presented as Means6SD. In all cases p ,0.05 was
considered statistically significant.
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